The relationship, structure and profiles of schizophrenia measurements: a post-hoc analysis of the baseline measures from a randomized clinical trial by Chen, Lei et al.
RESEARCH ARTICLE Open Access
The relationship, structure and profiles of
schizophrenia measurements: a post-hoc analysis
of the baseline measures from a randomized
clinical trial
Lei Chen
1*, Glenn Phillips
2, Joseph Johnston
1, Bruce J Kinon
1, Haya Ascher-Svanum
1, Sara Kollack-Walker
3,
Paul Succop
4 and Dieter Naber
5
Abstract
Background: To fully assess the various dimensions affected by schizophrenia, clinical trials often include multiple
scales measuring various symptom profiles, cognition, quality of life, subjective well-being, and functional
impairment. In this exploratory study, we characterized the relationships among six clinical, functional, cognitive,
and quality-of-life measures, identifying a parsimonious set of measurements.
Methods: We used baseline data from a randomized, multicenter study of patients diagnosed with schizophrenia,
schizoaffective disorder, or schizophreniform disorder who were experiencing an acute symptom exacerbation (n =
628) to examine the relationship among several outcome measures. These measures included the Positive and
Negative Syndrome Scale (PANSS), Montgomery-Asberg Depression Rating Scale (MADRS), Brief Assessment of
Cognition in Schizophrenia Symbol Coding Test, Subjective Well-being Under Neuroleptics Scale Short Form (SWN-
K), Schizophrenia Objective Functioning Instrument (SOFI), and Quality of Life Scale (QLS). Three analytic
approaches were used: 1) path analysis; 2) factor analysis; and 3) categorical latent variable analysis. In the optimal
path model, the SWN-K was selected as the final outcome, while the SOFI mediated the effect of the exogenous
variables (PANSS, MADRS) on the QLS.
Results: The overall model explained 47% of variance in QLS and 17% of the variance in SOFI, but only 15% in
SWN-K. Factor analysis suggested four factors: “Functioning,”“ Daily Living,”“ Depression,” and “Psychopathology.” A
strong positive correlation was observed between the SOFI and QLS (r = 0.669), and both the QLS and SOFI
loaded on the “Functioning” factor, suggesting redundancy between these scales. The measurement profiles from
the categorical latent variable analysis showed significant variation in functioning and quality of life despite similar
levels of psychopathology.
Conclusions: Researchers should consider collecting PANSS, SOFI, and SWN-K in their trials. This would allow a
broad spectrum of assessments that would have the ability to capture a wide range of treatment outcomes and
allow for a rich characterization of the subgroups involved. Additional research is needed to identify the critical
cognitive measures.
Trials registration: Clinical trials registration: Predicting Response to Risperidone Treatment Through Identification
of Early-onset of Antipsychotic Drug Action in Schizophrenia
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Schizophrenia is a complex, multidimensional disorder.
Patients diagnosed with schizophrenia exhibit positive,
negative, and mood symptoms as well as experience
cognitive and functional impairments. To fully assess
the various dimensions affected by schizophrenia, clini-
cal trials often include multiple scales measuring various
symptom profiles, cognition, quality of life, subjective
well-being, and functional impairment.
While the different measurement scales generally
assess diverse aspects of schizophrenia, these scales may
have some overlap in the constructs they measure. For
example, the Schizophrenia Objective Functioning
Instrument was designed to assess functioning, and the
Quality of Life Scale was designed to assess a patient’s
quality of life; however, both have domains that assess
occupational and psychosocial functioning. Therefore, it
seems reasonable to propose that both scales would
show some similarity (i.e., conceptual overlap of func-
tioning). The use of multiple scales that result in the
collection of redundant information may lead to
increased study burden (e.g., multiple scales, multiple
items per scale, and a 30- to 45-minute time require-
ment to administer each scale). Incorporating multiple
assessment scales may require more time and effort
from patients, additional staff time at study sites to
administer measures and record data which could cause
potential data quality issues, and an overall increased
cost of conducting clinical trials.
Recently, we published data from a prospective clinical
study in patients diagnosed with schizophrenia or a
related disorder showing that patients who exhibited
early response to antipsychotic treatment experienced
early and consistent improvement across multiple symp-
tom domains, subjective well-being, and health out-
comes [1,2]. In this exploratory study, we used baseline
data from this clinical trial to: 1) characterize the rela-
tionship among different symptomatic and functional
measures; and 2) identify a more parsimonious set of
measures that minimize conceptual overlap.
Methods
Study subjects
Data was obtained from a previously published clinical
trial undertaken to assess the efficacy of early onset of
antipsychotic drug action in schizophrenia [1,2]. Patients
(N = 628) who entered the study were diagnosed with
schizophrenia, schizoaffective disorder, or schizophreni-
form disorder. Patients had to be at least moderately ill
at the start of the study and experiencing an exacerba-
tion of their illness that required an intensification of
the level of psychiatric care during the 2 weeks before
entering the study.
The mean age of patients was 41.7 (standard deviation
[SD] = 10.9) years old, the mean age of their first psy-
chotic episode was 25.5 (SD = 9.8) years, 62% were
male, 44% of the patients were Caucasian, and 45% were
African American.
The original study protocol was approved by the ethi-
cal review boards responsible for individual study sites,
and all patients or their legal guardians gave written,
informed consent before entering the study. The study
was conducted in accordance with the Declaration of
Helsinki.
Assessment scales
Patients were evaluated at baseline using several differ-
ent assessment scales; key features of each measure are
summarized in Table 1.
The Positive and Negative Syndrome Scale (PANSS) is
a 30-item, clinician-rated instrument of positive, nega-
tive, and general psychopathology symptoms (each item
scored from 1 = absent to 7 = severe; total score ranging
from 30 to 210) [3]. The Montgomery-Asberg Depres-
sion Rating Scale (MADRS) is a 10-item, clinician-rated
scale for severity of depressive mood symptoms (each
item scored from 0 = absent to 6 = severe; total score
ranging from 0 to 60) [4].
The Brief Assessment of Cognition in Schizophrenia
Symbol Coding Test (BACS-SCT) is a tool for measur-
ing attention and the speed of information processing
[5].
The Subjective Well-being Under Neuroleptics Scale
Short Form (SWN-K) is a 20-item, patient-rated instru-
ment designed to capture a patient’s subjective well-
being (each item is scored 1 to 6; total score ranging
from 20 to 120 points) [6]. This scale was originally
developed with five conceptual domains using two posi-
tively worded and two negatively worded items per
d o m a i n .H o w e v e r ,i nap r e v i o u ss t u d ya n a l y z i n gt h e
structure of SWN-K using the same database, a 2-factor
solution was obtained based on how the items were
worded, namely a positively worded factor and a nega-
tively worded factor [7].
The Schizophrenia ObjectiveF u n c t i o n i n gI n s t r u m e n t
(SOFI) is a 49-item, clinician-rated instrument used to
assess living situation, instrumental activities of daily liv-
ing, productive activities, and social function as reported
by patient, caregiver, and treatment team with each
domain and overall rating scored from 1 to 100 (high
scores = normal or unimpaired functioning, and low
scores = severe impairment) [8].
T h eQ u a l i t yo fL i f eS c a l e( Q LS) is a 21-item, semi-
structured, interviewer-administered instrument that
covers the dimensions of intrapsychic foundations, inter-
personal relations, instrumental roles, and common
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impairment to 6 = high functioning; total score ranging
from 0 to 126) [9].
Statistical analysis
Path analysis for relationship among measures
To explore the relationships among multiple schizophre-
nia measures, Pearson correlation coefficients were cal-
culated, and structural equation modeling was used to
build path models using maximum likelihood estima-
tion. The total score of each measure was used. The
PANSS and MADRS assess symptoms, and the BACS-
SCT measures processing speed deficits which are
assumed to be more direct or proximal manifestations
of schizophrenia; therefore, the scores for these mea-
sures were designated as “exogenous variables” (predic-
tors) in this study. The SWN-K assesses subjective well-
being, and the SOFI and QLS measure functioning and
quality of life; these variables are assumed to change
more distally as a consequence of the proximal symp-
toms. Therefore, the scores for these measures were
designated as “endogenous variables” (outcomes). The
path parameters were fixeda t0( i . e . ,a r r o w sw e r e
deleted) for nonsignificant effects (i.e., p-value of esti-
mated effect > 0.1), and the path parameters were freed
(i.e., arrows were added) one at a time, as indicated by
the largest modification index calculated by the pro-
gram. The overall fit of the final model was assessed by
the root mean square error of approximation (RMSEA),
and the final optimal model was chosen for which the
Bayesian Information Criteria (BIC) was the least.
Since the measurements were on different scales, all
variables in the path model were standardized. Given
that the SWN-K had been selected as having the ulti-
mate outcome with the best model fit, a sensitivity ana-
lysis was implemented using QLS as the ultimate
outcome variable with the SWN-K and SOFI as the
effect mediators. Furthermore, in the path diagrams the
relationships were assumed to be linear. The linear rela-
tionship between variables was checked in separate sim-
ple regression analyses by including the quadratic term
in the model.
Exploratory factor analysis for measurement structure
To determine the overall factor structure of all the schi-
zophrenia measures, a total of 17 variables were used,
including the subdomains of the QLS, SOFI, PANSS,
SWN-K, and the overall ratings for BACS-SCT and
MADRS. Because we aimed to check the possible over-
lap and uniqueness of the measurements, an orthogonal
rotation (i.e., varimax) was selected in this analysis. A
Table 1 Properties of Each Measure Studied
Scales Description No. of Items Minutes Needed Minutes Needed Meaning of High Score
Clinician Patients good/bad
PANSS Psychopathologic symptoms 30 30-40 bad
Negative symptoms 7 bad
Positive symptoms 7 bad
Disorganized thoughts 7 bad
Hostility/excitement 4 bad
Anxiety/depression 4 bad
MADRS Depression 10 10 bad
BACS-SCT Digital symbol coding test 1 3 1.5 good
SWN-K Subjective well-being* 20 5-10 good
Positively worded statements 10 good
Negatively worded statements 10 bad
SOFI Objective functioning 49 30-45 good
Living situation 5 good
Instrumental activity of daily living 14 good
Productive activity 25 good
Social functioning 5 good
QLS Quality of life 21 30-45 good
Common objects and activities 2 good
Instrumental role 4 good
Interpersonal relations 8 good
Intrapsychic foundation 7 good
Abbreviations: BACS-SCT = Brief Assessment of Cognition in Schizophrenia Symbol Coding Test; MADRS = Montgomery-Asberg Depression Rating Scale; No. =
number; PANSS = Positive and Negative Syndrome Scale; QLS = Quality of Life; SOFI = Schizophrenia Objective Functioning Instrument; SWN-K = Subjective Well-
being Under Neuroleptics Short Form.
*For the SWN-K total score, each negatively-worded statement is reversed.
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tor if the loading was at least 0.3 and at least twice its
loading on any other factor. A variable was judged to
cross-load when its factor loadings were greater than 0.3
on more than one factor and the greatest factor loading
was not more than twice the other loadings.
Categorical latent variable analysis (CLVA) for measurement
profile
To determine the measurement profiles, a CLVA was
conducted using the same 17 variables used in the
exploratory factor analysis. CLVA assumes population
heterogeneity based on the analyzed measures and pro-
vides estimates for an individual’s probability of mem-
bership associated with each latent class. An individual
was assigned to the latent class for which the member-
ship probability was the highest.
Diagnostic statistics, such as the log-likelihood, Akaike
Information Criteria (AIC), BIC, and sample size-
adjusted BIC (aBIC), were considered in deciding the
number of classes. All analyses were carried out using
the Mplus software program (Version 5, Muthén &
Muthén, Los Angeles, CA, USA) [10].
Results
Pearson correlation coefficients among the various mea-
surement scales are shown in Table 2. The greatest cor-
relation was observed between the QLS and SOFI (r =
0.669). The second greatest correlation was observed
between the PANSS and SOFI (r = -0.407), followed clo-
sely by the correlation coefficients for PANSS and QLS
(r = -0.387), and the MADRS and SWN-K (r = -0.354).
Path model
Figure 1 summarizes the path analysis results. The
model was satisfactory in terms of the overall fit with an
c
2 p-value of 0.99 and a RMSEA of 0. In the optimal
path model depicting relationships among the measures,
the SWN-K was selected as the final outcome, while the
SOFI mediated the effect of the exogenous variables on
the QLS (Figure 1, Table 3). The path model explained
47% of the variance of QLS, 17% of the variance of
SOFI, and 15% of the variance of SWN-K. The PANSS
and MADRS were significantly correlated, while neither
the PANSS nor MADRS were significantly related with
BACS-SCT.
The standardized effects of the exogenous variables
PANSS, MADRS, and BACS-SCT on the endogenous
variables SOFI, QLS and SWN-K are shown in Table 3.
The MADRS appears to be predictive of SWN-K in a
direct way. One SD change of MADRS led to an
expected direct change of -0.33 SD in the SWN-K. The
indirect effect of MADRS on SWN-K via QLS was not
significant (p > 0.05). PANSS was predictive of QLS and
SOFI with a similar total effect (-0.37 SD and -0.40 SD,
respectively). BACS-SCT had weak effects on the SOFI
and QLS. The QLS and SOFI were highly correlated
with one SD change of SOFI, which led to an expected
direct change of 0.61 SD in QLS. About two-thirds of
the total PANSS effect on QLS was mediated by SOFI.
A sensitivity analysis (assuming QLS as the ultimate
outcome and SOFI and SWN-K as the mediators) did
not significantly change the variances explained by the
model.
Dimensionality of scales
The scree plot from the factor analysis suggested that
the eigenvalues are greater than one until the fifth
eigenvalue: eigenvalue = 5.15, 1.93, 1.57, 1.13, and 0.95
for factors 1 through 5, respectively. In addition, all the
loadings were below 0.3 on one factor when a 5-factor
solution was selected, so the 4-factor solution was
adopted.
Table 4 shows the results of the factor analysis
across the 17 variables. Four factors were identified.
The “Functioning” factor included all four subdomains
of the QLS, the instrumental activity of daily living,
productive activity, and social functioning of the SOFI,
and the negative symptoms factor of the PANSS. The
“Daily Living” factor included all 4 subdomains of the
SOFI, with the SOFI instrumental activity of daily liv-
ing subdomain loading most highly. Several SOFI sub-
scales cross loaded on both the “Functioning” and
“Daily Living” factors. The “Depression” factor
included the MADRS, the negatively worded state-
ments of the SWN-K, and the depression/anxiety fac-
tor of the PANSS. The “Psychopathology” factor
included 4 of the 5 PANSS factors-negative symptoms;
positive symptoms; disorganized thoughts; and hosti-
lity/excitement. The BACS-SCT and the positively
worded statements of the SWN-K did not load on any
identified factor.
Table 2 Pearson Correlation Coefficients among
Measurements
QLS SWN-K SOFI MADRS PANSS
QLS 1
SWN-K 0.202 1
SOFI 0.669 0.135 1
MADRS -0.161 -0.354 -0.097 1
PANSS -0.387 -0.160 -0.407 0.281 1
BACS-SCT 0.048 0.004 0.092 0.055 -0.041
Abbreviations: BACS-SCT = Brief Assessment of Cognition in Schizophrenia
Symbol Coding Test; MADRS = Montgomery-Asberg Depression Rating Scale;
PANSS = Positive and Negative Syndrome Scale; QLS = Quality of Life; SOFI =
Schizophrenia Objective Functioning Instrument; SWN-K = Subjective Well-
being Under Neuroleptics Short Form.
Pearson correlation coefficients are based on the following scores: QLS total
score, SWN-K total score, SOFI global rating, MADRS total score, PANSS total
score, and BACS symbol coding test (BACS-SCT).
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**p<0.001
BACSͲSCT PANSS MADRS
SOFI
R²=0.17 QLS
R²=0.47
SWNͲK
R²=0.15
Ͳ0.12**
0.28**
Ͳ0.40**
0.61**
Ͳ0.33** 0.08*
Ͳ0.04
0.06
Ͳ0.07*
ModelFitStatistics Chisquare
X²df p
RMSEA CFI TLI
0.458(5)0.994 0.000 1.000 1.019
Note:RMSEA=RootMeanSquareErrorofApproximation;CFI=ComparativeFixIndex;
TLI=TuckerͲLewisIndex
Figure 1 Path Model: Standardized Effects of Predictors on Outcome.
Table 3 Standardized Effects of the PANSS, MADRS and BACS-SCT
Exogenous Variable Endogenous Variable Standardized Effects
Direct Indirect Total
PANSS
SOFI -0.40** -0.40**
QLS -0.12** -0.25** -0.37**
SWN-K -0.05* -0.05*
MADRS
QLS -0.07* -0.07*
SWN-K -0.33** -0.01 -0.34**
BACS-SCT
SOFI 0.08* 0.08*
QLS 0.05* 0.05*
SWN-K 0.01 0.01
Abbreviations: BACS-SCT = Brief Assessment of Cognition in Schizophrenia Symbol Coding Test; MADRS = Montgomery-Asberg Depression Rating Scale; PANSS =
Positive and Negative Syndrome Scale; QLS = Quality of Life; SOFI = Schizophrenia Objective Functioning Instrument; SWN-K = Subjective Well-being Under
Neuroleptics Short Form.
*p < 0.05, **p < 0.001
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Table 5 summarizes the model-fit statistics for the cate-
gorical latent variable analyses with 1 to 4 latent classes.
A 3-class model stood out as the optimal solution in
terms of the highest likelihood and the smallest AIC,
BIC, and aBIC. In addition, a 3-class solution appeared
to provide a fair interpretation of the population with a
reasonable percentage in each class.
Figure 2 summarizes the 3-class measurement profiles.
Since the scale ranges vary greatly, the standardized
means were used in the graph. Patients in Class 1 (46%)
showed the least functional impairment on the QLS and
SOFI, and moderate severity in psychopathology on the
PANSS. Patients in Class 2 (24%) showed moderate
functional impairment on the QLS and SOFI, and mod-
erate severity in psychopathology on the PANSS.
Patients in Class 3 (30%) showed the greatest functional
impairment on the QLS and SOFI, and the greatest
severity in psychopathology on the PANSS.
Discussion
In this exploratory study, we aimed to quantitatively
characterize the relationships among clinical, functional,
cognitive, and quality-of-life measures, and to identify a
more parsimonious set of measurements. In the optimal
path model, the SWN-K was selected as the ultimate
outcome, although the overall model explained only
15% of variance in the SWN-K. The strongest correla-
tion was observed between the SOFI and the QLS. In
the path model, the effect of the PANSS (an exogenous
variable) on the QLS was mediated primarily by the
SOFI. The factor analysis suggested four factors: “Func-
tioning” (loading by SOFI, QLS, and PANSS negative),
“Daily Living” (loading by SOFI), “Depression” (loading
by MADRS, PANSS anxiety/depression factor, and
SWN-K negatively-asked questions), and “Psychopathol-
ogy” (loading by PANSS negative and positive symp-
toms, disorganized thoughts, and hostility/excitement
factors). In addition, the measurement profile analysis
revealed three classes that generally followed a pattern
from less severely impaired on measures of functioning
(QLS, SOFI) and less severely ill (PANSS) (Class 1) to
Table 4 Factor Analysis of Scales
Functioning Daily Living Depression Psychopathology
QLS
Common objects and activities 0.61 0.29 0.04 0.22
Intrapsychic foundation 0.80 0.24 0.05 0.20
Interpersonal relations 0.70 0.16 0.15 0.05
Instrumental role 0.59 0.17 0.04 0.00
MADRS -0.11 0.04 -0.69 -0.08
SOFI
Living situation 0.24 0.54 -0.02 0.20
Instrumental activity of daily living 0.40 0.78 0.01 0.24
Productive activity 0.48 0.56 0.05 0.14
Social functioning 0.57 0.54 0.12 0.14
SWN-K
Positively worded statements 0.23 0.02 0.22 0.00
Negatively worded statements -0.08 -0.04 -0.43 0.02
PANSS
Negative symptoms -0.37 -0.12 -0.16 -0.40
Positive symptoms -0.13 -0.05 -0.13 -0.44
Disorganized thoughts -0.24 -0.10 0.09 -0.94
Hostility/excitement 0.01 -0.10 -0.17 -0.35
Anxiety/depression 0.02 0.01 -0.80 -0.16
BACS-SCT -0.02 0.11 -0.06 0.20
Abbreviations: BACS-SCT = Brief Assessment of Cognition in Schizophrenia Symbol Coding Test; MADRS = Montgomery-Asberg Depression Rating Scale; PANSS =
Positive and Negative Syndrome Scale; QLS = Quality of Life; SOFI = Schizophrenia Objective Functioning Instrument; SWN-K = Subjective Well-being Under
Neuroleptics Short Form.
Bolded text indicates significant loading or cross-loading.
Table 5 Model-Fitting Statistics for Measurement Profile
(Categorical Latent Variable Analyses)
Number of Class 1 2 3 4
Log likelihood -37759 -36834 -36004 -36425
BIC 75629 73838 72459 73137
aBIC 75736 74003 72237 73417
AIC 75586 73772 72148 73026
Abbreviations: AIC = Akaike Information Criteria; aBIC = Adjusted Bayesian
Information Criteria; BIC = Bayesian Information Criteria.
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Page 6 of 10moderately impaired on functioning (Class 2), and most
severely impaired on functioning and psychopathology
(Class 3).
Our findings suggest that redundancy exists among
the measures studied, particularly among the clinician-
rated functional and quality of life measures. The Pear-
son correlation coefficients among measurements
revealed the strongest correlation between the SOFI and
the QLS (r = .669). Previously, during development and
validation of the SOFI, psychometric properties also
revealed a moderate correlation between the SOFI and
QLS, similar in magnitude to the one observed in the
current study with a correlation coefficient of r = .61 for
the patient-rated version of the SOFI and r = .52 for the
informant version [8]. In addition, the path model
explained 47% of the variance in the QLS, and a major-
ity of this effect was mediated by SOFI, suggesting over-
lap between QLS and SOFI. Furthermore, while the
QLS loaded on “Functioning,” the SOFI loaded on both
the “Functioning” and “Daily Living” factors. While both
the SOFI and QLS provide, to some degree, a measure
of social and occupational functioning, the SOFI pro-
vided a broader measure of outcomes that included
functioning and daily living.
The best-fit model for the path analysis, which
selected the SWN-K to be the ultimate outcome,
revealed that only 15% of the variance in SWN-K could
be explained by the model, which included measures of
symptoms, functioning, and cognition. This finding may
suggest that the SWN-K is a unique measure capturing
potential treatment effects not captured by the other
measurement scales. The SWN-K negatively worded
statements loaded on the “Depression” factor, while the
SWN-K positively worded statements did not meet the
factor-loading criteria. This latter finding may suggest
important differences between these two components of
the SWN-K, a finding that was consistent with a recent
factor and item response theory analysis on the English
version of SWN-K [7]. Additional work will be necessary
to further understand the relationship of the positively
Figure 2 Measurement Profiles. Abbreviations: BACS-SCT = Brief Assessment of Cognition in Schizophrenia Symbol Coding test; MADRS =
Montgomery-Asberg Depression Rating Scale; PANSS = Positive and Negative Syndrome Scale; QLS = Quality of Life; SOFI = Schizophrenia
Objective Functioning Instrument; SWN-K = Subjective Well-being Under Neuroleptics Short Form.
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properties of the scale as a whole, and the unique quali-
ties of the SWN-K to overall treatment responsiveness.
The SWN-K total score has been demonstrated pre-
viously to be associated with dopaminergic D2 receptor
blockade [11], medication adherence [12], and the likeli-
hood of achieving enduring symptomatic remission [13].
Subjective well-being has also been associated with
depression. In patients with schizophrenia, depressive
symptoms were significantly associated with subjective
well-being in newly admitted patients [14] and during
the course of acute treatment with atypical antipsycho-
tics [15]. In these studies, a significant negative correla-
tion was observed between the SWN-K score, the
PANSS depression factor score, and the subjectively-
rated Beck Depression Inventory (BDI) [14,15], although
only the correlation between the SWN-K and BDI was
significant following 8 weeks of treatment [15]. These
findings are consistent with the factor analysis in which
the SWN-K negatively worded statements loaded on the
“Depression” factor. In the path analysis, the physician-
rated MADRS was predictive of the SWN-K in a direct
fashion, with a one SD change of the MADRS leading to
ac h a n g eo f- 0 . 3 3S Di nt h eS W N - K .I na d d i t i o n ,t h e
correlation analysis had revealed a small to moderately
sized negative correlation between the MADRS and
SWN-K (r = -0.35). These findings collectively highlight
the important role that depressive symptoms may play
in low subjective well-being, and the importance of a
patient’s subjective well-being to treatment outcomes,
including medication adherence and remission.
The measurement profiles of the study population
detected heterogeneity primarily in measurements of
social and occupational functioning and daily living
activities via the SOFI and QLS, whereas the study
population was generally homogeneous in psychopatho-
logical symptoms, as defined by the study inclusion cri-
teria. Patients in Class 3 stood out as having the worst
functioning and daily living and the worst or most
severe symptoms. Patients in Classes 1 and 2 had mod-
erately severe symptoms, with patients in Class 1 having
the best functioning and daily living, while patients in
Class 2 had moderately impaired functioning and daily
living. Patients in Class 1 with the best functioning and
daily living also seemed to show somewhat higher scores
on SWN-K positively worded statements.
The BACS-SCT, or symbol coding test, is a measure
of attention and speed of information processing [5]. A
recent meta-analysis of 37 studies comparing digit sym-
bol coding tasks to other cognitive measures in schizo-
phrenia demonstrated a significantly larger mean effect
size for impairment in digit symbol coding compared
with the effects of impairment in episodic memory,
executive function, and working memory, suggesting
that information processing inefficiency is a central fea-
ture of the cognitive deficit in schizophrenia [16]. A
subsequent study examining the predictive relationships
between neuropsychological domains, functional compe-
tence, social competence, symptoms, and real-world
behavior demonstrated that only processing speed had
both direct and indirect effects on all three real-world
behaviors including domains ofw o r ks k i l l s ,i n t e r p e r s o -
nal relationships, and community activities [17].
Reduced processing speed has been associated with
functional disability observed in patients with schizo-
phrenia [18,19]. In previous research, we found informa-
tion processing speed had both direct and indirect
effects via negative symptoms on three domains of func-
tioning, as measured by the QLS at baseline and follow-
ing 24 weeks of antipsychotic treatment [20].
In the current analysis, the BACS-SCT did not play a
major role in any of the current analyses including the
path-modeling and factor analysis. Previously, we used a
composite measure of processing speed that included an
average of two subscales including digit symbol coding
and the verbal fluency scale, and that focused on QLS
domains of functioning as the ultimate outcome [20].
Perhaps the use of only the digit symbol coding test
underlies the different findings. It would be legitimate to
argue that the limited role of the BACS-SCT observed
in these analyses suggests that this test may also be cap-
turing unique information. However, in contrast to the
SWN-K, which showed a mild to moderate correlation
with the QLS, SOFI, and MADRS, the BACS-SCT was
not significantly related to any of the clinical or func-
tional measures evaluated in this study.
Our findings from the path analysis using structural
equation modeling, the factor analysis of the measurement
structure, and the measurement profiles from the latent
class analysis complement each other in understanding
the measurements. Though each model was implemented
under different assumptions, the findings that QLS and
SOFI measures were highly correlated was consistent. The
MADRS and SWN-K were also correlated, while the
BACS-SCT was not significantly related with any of the
other measures. This study may contribute to the effort to
better understand schizophrenia measurements with the
goal of identifying a parsimonious data set.
There were several limitations to the current analyses.
First, patients had to have a particular level of acuity to
enter the study, and this likely restricted the possible
range of baseline scores on the PANSS. Second, for the
path analysis, an assumption was made that the PANSS,
MADRS, and BACS-SCT were “exogenous variables”
assessing symptoms and attention and processing speed
deficits assumed to be more proximal to disease mani-
festation. Additionally, it was assumed that the SWN-K,
SOFI, and QLS were “endogenous variables” assessing
Chen et al. BMC Psychiatry 2011, 11:203
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thought to be the consequences of the proximal symp-
toms. However, our previous work has demonstrated
that subjective well-being, functioning, and quality of
life can change as early as 2 weeks into treatment and
seemingly mirror improvements in symptoms [2]. Thus,
the temporal relationship of change among these vari-
ables is not fully understood, and the outcomes
observed are thereby limited by the proposed relation-
ships set forth by the specifications of the statistical
models. Third, we incorporated the SWN-K total score
in the correlation and path analyses and the SWN-K
positively worded and negatively worded statements in
the factor analysis and measurement profiles. Therefore,
comparisons for the SWN-K total score cannot be made
across all of the analyses.
This study was exploratory in nature, with the results
being driven by both statistics and knowledge of the dis-
ease and population. Further, even a perfect fit of the
model would not prove that the inferences are causal,
but merely suggest that the model fits the data well. It
would be helpful to attempt to replicate the results for a
similar population at a different time, and/or to replicate
the results in a different patient population with similar
or varying disease characteristics. It is important to rea-
lize that results of this study reflect a chronically ill
patient population moderately to severely ill with an
exacerbation of symptoms, and the observations made
are dependent upon the scales incorporated in the study
design and assessed at baseline.
Conclusions
Researchers should consider collecting PANSS, SOFI,
and SWN-K in their trials. This would allow a broad
spectrum of assessments that would have the ability to
capture a wide range of treatment outcomes and allow
for a rich characterization of the subgroups involved.
Additional research is needed to identify the critical
cognitive measures.
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